Monthly cycles of a 5-day FMD (plant-based, low-calorie, and low-protein) followed by a normal diet appeared to improve markers of prediabetes and immune system aging.
In patients with HFpEF and obesity, symptom reduction and weight loss provided by semaglutide extends to those with diabetes, suggest new data from the STEP-HFpEF DM trial.
Empagliflozin did not significantly reduce overall HF hospitalization or all-cause death in high-risk patients in EMPACT-MI but did reduce first and total hospitalizations.
SGLT2 inhibitors not only were safe in adult patients with congenital heart disease who develop heart failure but also were associated with reduced hospitalizations.